ClinicalTrials.gg
Not yet recruitingNCT07949344Updated Nov 19, 2026

A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)

A Phase 4 interventional study of Quizartinib and Chemotherapy in Acute Myeloid Leukemia, sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (part of Daiichi Sankyo) · Phase 4, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo — 2 open to participants now, 4 under way, 1 of them phase 3. Leukemia, Myeloid, Acute · Daiichi Sankyo.

Planned enrollment
12th of 21
40 · median 50
Started
2026
the only one that year
Phase 4
Only one
of the 22
Registered
22nd of 22
by date

Among the 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 12th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 4, and was the 22nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

2 of the 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, or all of them as a file.
02

Study summary

The clinical trial is designed to assess the safety of quizartinib in newly diagnosed FLT3-ITD (+) AML in Chinese participants.

Read the detailed description

This is a Phase 4, open-label, single-arm, interventional trial evaluating the safety and efficacy of quizartinib administered in combination with induction and consolidation chemotherapy and administered as maintenance monotherapy in Chinese adult participants with newly diagnosed FLT3-ITD (+) AML. Eligible participants will be administered quizartinib in combination with chemotherapy in the Induction and Consolidation Phases and administered with quizartinib monotherapy in the Maintenance Phase. The trial will be divided into 3 periods: screening period, treatment period (Induction Phase, Consolidation Phase, and Maintenance Phase), and long-term follow-up (LTFU) period.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Quizartinib
  • FLT3-ITD (+)
  • Acute Myeloid Leukemia
  • AML
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

To be eligible to participate in this trial, an individual must meet all the following criteria:

  1. Sign and date the form (ICF), prior to the start of any trial-specific qualification procedures.
  2. Greater than or equal to (≥)18 years or the minimum legal adult age (whichever is greater) and less than or equal to (≤)75 years (at Screening).
  3. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening).
  4. (ECOG) performance status of 0 to 2 at Screening.
  5. Participant has confirmed FLT3-ITD (+) activating mutation present at ≥5 percent (%) variant allele frequency (VAF) (or ≥0.05 signal ratio/allelic ratio [SR/AR]) from the first diagnosis in bone marrow or peripheral blood as determined by an approved or adequately validated FLT3 mutation assay prior to initial treatment.
  6. Participant is receiving standard "7+3" induction chemotherapy regimen as specified in the protocol.

Key Exclusion Criteria:

Individual who meets any of the following criteria will be excluded from participation in this trial:

  1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation t(15;17)(q22;q12), or Breakpoint Cluster Region-Abelson murine leukemia viral oncogene homolog (BCR-ABL) positive leukemia.
  2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms.
  3. Prior treatment for AML, except for the following allowances:

    1. Leukapheresis;
    2. Treatment for hyperleukocytosis with hydroxyurea;
    3. Cranial radiotherapy for central nervous system (CNS) leukocytosis;
    4. Prophylactic intrathecal chemotherapy;
    5. Growth factor/cytokine support;
  4. Prior treatment with quizartinib or other FLT3-ITD inhibitors.

Note: Other protocol pre-specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Quizartinib + Standard Chemotherapy

    Participants will receive up to 2 cycles of induction chemotherapy along with quizartinib 40 mg orally once daily for 14 days starting at Day 8 of Cycle 1, followed by up to 4 cycles of consolidation chemotherapy along with quizartinib 40 mg orally once daily for 14 days starting Day 6, with optional allogeneic hematopoietic stem cell transplantation \[HSCT\]), followed by up to 36 cycles of maintenance monotherapy with quizartinib 30 mg orally once daily, on Cycle 1 Day 1 increased to 60 mg once daily on Cycle 1 Day 16.

    Drug: Quizartinib · Drug: Chemotherapy · Genetic: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Interventions

  • DrugQuizartinib

    Participants will receive quizartinib 40 mg orally once daily for 14 days during the induction and consolidation phases and 30 mg orally once daily, increased to 60 mg once daily in the maintenance phase.

  • DrugChemotherapy

    Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).

    Also known as: Daunorubicin, Idarubicin, Standard Chemotherapy, Cytarabine

  • GeneticAllogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Allogeneic HSCT is one of the options for consolidation therapy.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Grade Greater than or Equal to (≥)3 Treatment-Related Adverse Events (TRAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TRAEs are defined as those AEs considered to be related to quizartinib by the investigators with start or worsening date during the on-treatment period (from the first dose date of quizartinib to 30 days after the last dose date of quizartinib).

    Time frame: Up to approximately 39 months

Secondary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    Other safety parameters may also be assessed. These include serious TEAEs, adverse events of special interests (AESIs), changes in vital signs, electrocardiogram (ECG) findings, safety laboratory assessments and physical examinations.

    Time frame: Up to approximately 39 months

  2. Composite Complete Remission (CRc) Rate

    CRc rate is defined as the percentage of participants who achieved composite complete remission (CRc), where CRc is defined as complete remission (CR) + complete remission with incomplete neutrophil or platelet recovery (CRi) after induction.

    Time frame: At the end of induction, up to 2 cycles (each cycle=28 days)

  3. Complete Remission (CR) Rate

    CR rate is defined as percentage of participants who achieved a CR after induction.

    Time frame: At the end of induction, up to 2 cycles (each cycle=28 days)

  4. Event-Free Survival (EFS)

    EFS is defined as time from enrollment until the date of the earliest of any of the following: refractory disease (or treatment failure) which is determined at the end of the induction phase; relapse after CR or CRi; death from any cause since enrollment.

    Time frame: Up to approximately 39 months

  5. Relapse-Free Survival (RFS)

    RFS is defined as the time from enrollment, for participants who achieve CR or CRi in the induction phase, until documented relapse or death from any cause, whichever comes first.

    Time frame: Up to approximately 39 months

  6. Overall Survival (OS)

    OS is defined as the time from enrollment until death from any cause.

    Time frame: Up to approximately 39 months

  7. Plasma Concentration of Quizartinib and AC886

    Time frame: Up to approximately 39 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2030, 42 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949344
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Contact for Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion